Skip to main content
Clinical Trials/JPRN-UMIN000016167
JPRN-UMIN000016167
Completed
Phase 2

Phase II study of the effectiveness of prophylaxis against side effects associated with Afatinib (NLCTG 1401) - Phase II study of the effectiveness of prophylaxis against side effects associated with Afatinib (NLCTG 1401)

iigata Lung Cancer Treatment Group0 sites30 target enrollmentJanuary 9, 2015

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
non-small cell lung cancer
Sponsor
iigata Lung Cancer Treatment Group
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 9, 2015
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
iigata Lung Cancer Treatment Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)History of active double cancer (2\)No intention to birth control (3\)Unstable psychic disorder (4\)Interstitial pneumonia or active radiation pneumonia or drug\-induced pneumonia (5\)Ileus (6\)Patients who can not take oral drugs (7\)Severe complications (8\)Patients in drug and tetracycline drug used in the present study a history of hypersensitivity (9\)Decision of ineligibility by a physician.

Outcomes

Primary Outcomes

Not specified

Similar Trials